Fingerprint
Dive into the research topics of 'Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer
Khanh Do, Giovanna Speranza, Rachel Bishop, Sonny Khin, Larry Rubinstein, Robert J. Kinders, Manuel Datiles, Michelle Eugeni, Michael H. Lam, L. Austin Doyle, James H. Doroshow, Shivaani Kummar
Research output: Contribution to journal › Article › peer-review
100
Scopus
citations